[Reduction in acute myocardial infarction mortality over a five-year period]

Rev Esp Cardiol. 2006 Mar;59(3):200-8.
[Article in Spanish]

Abstract

Introduction and objectives: To assess recent changes in the management of patients with acute myocardial infarction (AMI) and their impact on mortality using data from the PRIAMHO I and II registries (1995 and 2000).

Patients and method: Of the 168 public hospitals in Spain, 24 and 58 contributed to the 1995 and 2000 PRIAMHO registries, respectively.

Results: Patients in the PRIAMHO II registry (n=6221) were significantly older, more often female, and proportionally more likely to have coronary risk factors or a previous myocardial infarction, or to have undergone revascularization than those in PRIAMHO I (n=5242). Reperfusion therapy was administered more often (46.9% vs 41.9%, P<.001) and earlier (48 min vs 60 min, P<.001). Antiplatelet drugs were given to 96.1% vs 89.1% of patients, beta-blockers to 51.1% vs 30.1%, and ACE inhibitors to 41.6% vs 24.9% (P<.001 for all comparisons). In addition, 28-day mortality was 11.3% and 14.2% (P<.001), respectively, and one-year mortality, 16.4% and 18.5% (P<.001), respectively. The adjusted hazard ratio for mortality at one year in PRIAMHO II compared with PRIAMHO I was 0.78 (95% CI, 0.70-0.86, P<.001; adjusted for age, sex, diabetes, smoking, dyslipemia, hypertension, previous MI and CABG, ST-elevation status and Killip class at admission, and hospital characteristics).

Conclusions: Even though patients registered in 2000 formed a higher risk group than those registered in 1995, one-year mortality after AMI decreased by 22% over the five-year period. This improvement was due to more frequent and earlier reperfusion therapy and better use of antithrombotics, beta-blockers and ACE inhibitors.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Age Factors
  • Angioplasty, Balloon, Coronary
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Data Interpretation, Statistical
  • Electrocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / mortality*
  • Myocardial Infarction / therapy
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Recurrence
  • Registries*
  • Risk Factors
  • Sex Factors
  • Spain
  • Survival Analysis
  • Time Factors

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Platelet Aggregation Inhibitors